Entrada Therapeutics reports Q3 2022 net loss of $25.1M; cash runway into H2 2024

Entrada Therapeutics, Inc.

2022-Q3 EPS reported -$2.24

Cash, cash equivalents and marketable securities of $215.6M as of Sept 30, 2022, down from $291.1M at Dec 31, 2021.
Net loss for Q3 2022 was $25.1M, compared to $14.4M in Q3 2021.
R&D expenses increased to $19.0M (Q3 2022) from $10.5M (Q3 2021); G&A expenses rose to $7.0M from $3.9M.
On track to file IND for ENTR-601-44 (Duchenne exon 44 skipping) in Q4 2022; second IND for ENTR-701 (DM1) planned for H2 2023.
Preclinical data for ENTR-701 presented at World Muscle Society; collaboration entered with Myotonic Dystrophy Clinical Research Network.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Entrada Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss for the third quarter of 2022 was $25.1 million.

Period: the quarter ended September 30, 2022
Net income: Net loss for the third quarter of 2022 was $25.1 million
Result: reported results

Exact text from the filing

Net loss for the third quarter of 2022 was $25.1 million, compared to $14.4 million for the same period of 2021.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001689375-22-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.